Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study

Table 4 Adverse events reported by ≥ 10% of patients who received adjuvant S-1 plus oxaliplatin chemotherapy

Event	Adjuvant SOX (n = 124)
	Grade 1	Grade 2	Grade 3	Grade 4	All grade	Grade 3 or 4
	No. of patients				%
Leukopenia	46	18	8	3	60.5	8.9
Neutropenia	34	31	19	9	75	22.6
Anemia	35	3	1	1	32.3	1.6
Thrombocytopenia	22	18	7	0	37.9	5.6
Elevated total serum bilirubin level	23	2	1	0	21	0.8
Elevated AST/ALT level	53	5	1	1	48.4	1.6
Elevated ALP level	12	3	1	0	12.9	0.8
Nausea	41	19	4	-	51.6	3.2
Vomiting	17	16	4	0	29.8	3.2
Diarrhea	33	7	1	0	33.1	0.8
Peripheral sensory neuropathy	61	4	0	-	52.4	0

Grades of adverse events were defined according to the Common Terminology Criteria for Adverse Events (Version 4.0). SOX: S-1 plus oxaliplatin; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; -: Not available.